Published in TB and Outbreaks Week, January 25th, 2005
Jonathan Fishbein, MD, said officials at the U.S. National Institutes of Health (NIH) overlooked problems with the way the study was conducted on the drug, nevirapine, which was being used to protect babies in Africa from HIV infection during birth.
Fishbein testified before a panel of scientists at the independent Institute of Medicine. The NIH, which maintains that the drug is safe in single doses, asked the institute to conduct the review.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.